AbbVie Inc.
ABBV · NYSE
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Market Cap | $314 | $274 | $286 | $240 |
| - Cash | $6 | $13 | $9 | $10 |
| + Debt | $68 | $60 | $64 | $78 |
| Enterprise Value | $377 | $321 | $341 | $307 |
| Revenue | $56 | $54 | $58 | $56 |
| % Growth | 3.7% | -6.4% | 3.3% | – |
| Gross Profit | $39 | $34 | $41 | $39 |
| % Margin | 70% | 62.4% | 70% | 69% |
| EBITDA | $15 | $17 | $24 | $24 |
| % Margin | 26.5% | 31.6% | 41.6% | 42.6% |
| Net Income | $4 | $5 | $12 | $12 |
| % Margin | 7.6% | 9% | 20.4% | 20.5% |
| EPS Diluted | 2.39 | 2.72 | 6.63 | 6.45 |
| % Growth | -12.1% | -59% | 2.8% | – |
| Operating Cash Flow | $19 | $23 | $25 | $23 |
| Capital Expenditures | -$1 | -$1 | -$1 | -$1 |
| Free Cash Flow | $18 | $22 | $24 | $22 |